We are live on ! Find out more
NVS icon

Novartis

1,172 hedge funds and large institutions have $24.4B invested in Novartis in 2019 Q4 according to their latest regulatory filings, with 156 funds opening new positions, 412 increasing their positions, 387 reducing their positions, and 55 closing their positions.

New
Increased
Maintained
Reduced
Closed

184% more first-time investments, than exits

New positions opened: 156 | Existing positions closed: 55

64% more funds holding in top 10

Funds holding in top 10: 1423 (+9)

55% more call options, than puts

Call options by funds: $200M | Put options by funds: $129M

15% more capital invested

Capital invested by funds: $21.2B → $24.4B (+$3.18B)

8% more funds holding

Funds holding: 1,0901,172 (+82)

6% more repeat investments, than reductions

Existing positions increased: 412 | Existing positions reduced: 387

0.54% more ownership

Funds ownership: 9.57%10.11% (+0.54%)

Holders
1,172
Holders Change
+82
Holders Change %
+7.52%
% of All Funds
23.09%
Holding in Top 10
23
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+64.29%
% of All Funds
0.45%
New
156
Increased
412
Reduced
387
Closed
55
Calls
$200M
Puts
$129M
Net Calls
+$71M
Net Calls Change
+$62.6M
Name Holding Trade Value Shares
Change
Change in
Stake
GGI
126
Godsey & Gibb Inc
Virginia
$15.9M +$318K +3,545 +2%
Voloridge Investment Management
127
Voloridge Investment Management
Florida
$15.8M -$1.14M -12,712 -7%
CIM
128
Corda Investment Management
Texas
$15.6M +$65.8K +733 +0.4%
TD Asset Management
129
TD Asset Management
Ontario, Canada
$15.2M -$91.3K -1,017 -0.6%
Allianz Asset Management
130
Allianz Asset Management
Germany
$15.1M +$975K +10,865 +7%
BCAM
131
Boston Common Asset Management
Massachusetts
$14.8M +$10.3K +115 +0.1%
JGUA
132
John G. Ullman & Associates
New York
$14.7M -$249K -2,775 -2%
TBC
133
Tweedy, Browne Co
Connecticut
$14.6M -$121K -1,345 -0.9%
UBS AM
134
UBS AM
Illinois
$14.2M -$3.82M -42,547 -22%
GJIC
135
Gamble Jones Investment Counsel
California
$13.9M -$189K -2,108 -1%
Massachusetts Financial Services
136
Massachusetts Financial Services
Massachusetts
$13.4M -$2.32M -25,854 -15%
Mirae Asset Global Investments
137
Mirae Asset Global Investments
South Korea
$13.3M +$1.69M +18,783 +15%
SI
138
Scout Investments
Missouri
$13.1M -$309K -3,444 -2%
FNBOO
139
First National Bank of Omaha
Nebraska
$13M +$158K +1,756 +1%
FNBT
140
FineMark National Bank & Trust
Florida
$13M +$465K +5,178 +4%
RFA
141
Reilly Financial Advisors
California
$13M +$549K +6,118 +5%
RG
142
Renaissance Group
Kentucky
$12.8M -$23.7K -264 -0.2%
NPF
143
Norris Perne & French
Michigan
$12.6M -$54.6K -608 -0.5%
PNC
144
Park National Corp
Ohio
$12.6M -$188K -2,100 -2%
CCM
145
Chilton Capital Management
Texas
$12.4M -$41.8K -466 -0.4%
EPAM
146
Euro Pacific Asset Management
Puerto Rico
$12.1M +$11.4M +127,597 New
Connor, Clark & Lunn Investment Management (CC&L)
147
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$12M -$2.37M -26,425 -17%
GD
148
Grandfield & Dodd
New York
$12M +$151K +1,680 +1%
OCAM
149
Onex Canada Asset Management
Ontario, Canada
$12M +$1.35M +15,030 +13%
Adage Capital Partners
150
Adage Capital Partners
Massachusetts
$11.8M +$11.2M +125,000 New

NVS Hedge Fund Activity: Q4 2019 in Review

1,172 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q4 2019, worth a combined $24.4B — up 15% from $21.2B a quarter earlier.

Buyers outnumbered sellers: 156 funds opened new NVS positions and 55 closed out — a net gain of 101 holders — while 412 added to existing stakes and 387 trimmed.

The largest buyer was Loomis, Sayles & Company, adding an estimated $284M. The largest seller was Dodge & Cox, cutting an estimated $140M.

  • 1,172 institutional investors held Novartis (NVS) as of Q4 2019, up from 1,090 in Q3 2019.
  • Funds reported $24.4B of Novartis stock for Q4 2019, up 15% quarter-over-quarter.
  • 156 funds opened new Novartis positions in Q4 2019 and 55 closed out, a net change of +101 holders.
  • The largest Novartis buyer in Q4 2019 was Loomis, Sayles & Company, an estimated $284M added.
  • The largest Novartis seller in Q4 2019 was Dodge & Cox, an estimated $140M sold.

Based on aggregated 13F filings for Q4 2019.